Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2010 Feb;3(2):128-31.
doi: 10.1158/1940-6207.CAPR-09-0268. Epub 2010 Jan 26.

Assessing efficacy in early-phase cancer prevention clinical trials: the case of ki-67 in the lung

Eva Szabo  1
Affiliations
Review

Assessing efficacy in early-phase cancer prevention clinical trials: the case of ki-67 in the lung

Eva Szabo. Cancer Prev Res (Phila). 2010 Feb.

Abstract

This perspective on Kim et al. (beginning on p. 148 in this issue of the journal) examines the value of the Ki-67 proliferation index as a surrogate end point in early-phase clinical lung cancer prevention trials. The clinical trial of Kim et al. shows an effect of the cyclooxygenase-2-selective inhibitor celecoxib at a high dose on Ki-67 expression in the normal bronchial epithelia of current and former smokers. The critical issue of how these data can be used to further drug development is discussed.

PubMed Disclaimer

Conflict of interest statement

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Comment on

Similar articles

  • Lung cancer chemoprevention with celecoxib in former smokers.
    Mao JT, Roth MD, Fishbein MC, Aberle DR, Zhang ZF, Rao JY, Tashkin DP, Goodglick L, Holmes EC, Cameron RB, Dubinett SM, Elashoff R, Szabo E, Elashoff D. Mao JT, et al. Cancer Prev Res (Phila). 2011 Jul;4(7):984-93. doi: 10.1158/1940-6207.CAPR-11-0078. Cancer Prev Res (Phila). 2011. PMID: 21733822 Free PMC article. Clinical Trial.
  • Biological activity of celecoxib in the bronchial epithelium of current and former smokers.
    Kim ES, Hong WK, Lee JJ, Mao L, Morice RC, Liu DD, Jimenez CA, Eapen GA, Lotan R, Tang X, Newman RA, Wistuba II, Kurie JM. Kim ES, et al. Cancer Prev Res (Phila). 2010 Feb;3(2):148-59. doi: 10.1158/1940-6207.CAPR-09-0233. Epub 2010 Jan 26. Cancer Prev Res (Phila). 2010. PMID: 20103722 Free PMC article. Clinical Trial.
  • Celecoxib decreases Ki-67 proliferative index in active smokers.
    Mao JT, Fishbein MC, Adams B, Roth MD, Goodglick L, Hong L, Burdick M, Strieter ER, Holmes C, Tashkin DP, Dubinett SM. Mao JT, et al. Clin Cancer Res. 2006 Jan 1;12(1):314-20. doi: 10.1158/1078-0432.CCR-05-1440. Clin Cancer Res. 2006. PMID: 16397057 Clinical Trial.
  • COX-2 inhibition and lung cancer.
    Sandler AB, Dubinett SM. Sandler AB, et al. Semin Oncol. 2004 Apr;31(2 Suppl 7):45-52. doi: 10.1053/j.seminoncol.2004.03.045. Semin Oncol. 2004. PMID: 15179623 Review.
  • Chemoprophylaxis of colon cancer.
    Reddy BS, Rao CV. Reddy BS, et al. Curr Gastroenterol Rep. 2005 Oct;7(5):389-95. doi: 10.1007/s11894-005-0009-x. Curr Gastroenterol Rep. 2005. PMID: 16168238 Review.
See all similar articles

Cited by

References

    1. Szabo E. Selecting targets for cancer prevention: Where do we go from here? Nat Rev Cancer. 2006;6:867–74. - PubMed
    1. Schatzkin A, Gail M. The promise and peril of surrogate end points in cancer research. Nature Rev. 2002;2:1–9. - PubMed
    1. Lippman SM, Lee JS, Lotan R, Hittelman W, Wargovich MJ, Hong WK. Biomarkers as intermediate end points in chemoprevention trials. J Natl Cancer Inst. 1990;82:555–60. - PubMed
    1. Szabo E. Assessing efficacy in early-phase cancer prevention trials: The case of oral premalignancy. Cancer Prev Res. 2009;1:312–315. - PubMed
    1. Kim ES, Hong WK, Lee JJ, et al. Biologic activity of celecoxib in the bronchial epithelium of current and former smokers. Cancer Prev Res. 2010;3 - PMC - PubMed

MeSH terms